Literature DB >> 8219182

Six years' experience with the discontinuation of BCG vaccination. 2. Cost and benefit of mass BCG vaccination.

L Trnka1, D Danková, E Svandová.   

Abstract

In 1986 the compulsory mass BCG vaccination of infants born in a selected area of the Czech Republic was abolished. The observed annual risk of tuberculous infection in children aged 0-6 years was below 0.1% and the annual risk of tuberculous disease 7/100,000. The increase of tuberculous cases among nonvaccinated children indicated a protective efficacy of BCG vaccine of 80%. A benefit analysis proved that the advantages and disadvantages of BCG vaccination were in balance. The number of nonvaccinated children developing tuberculosis was so small that mass application of BCG has been found to be redundant. The important advantage of not using the vaccination is the maintenance of the epidemiological and diagnostic value of tuberculin tests. The tests in connection with preventive chemotherapy remain an important tool, enabling control of infected individuals.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8219182     DOI: 10.1016/0962-8479(93)90056-4

Source DB:  PubMed          Journal:  Tuber Lung Dis        ISSN: 0962-8479


  3 in total

1.  Infant tuberculosis in Austria--trend reversal since 1990?

Authors:  A Makristathis; F Stauffer; J P Klein; M L Rotter; G Wewalka; A M Hirschl
Journal:  Infection       Date:  1998 Jan-Feb       Impact factor: 3.553

2.  Paediatric tuberculosis during universal and selective Bacillus Calmette-Guérin vaccination policy: a nationwide population-based retrospective study, Finland, 1995-2015.

Authors:  Antti Kontturi; Satu Kekomäki; Hanna Soini; Jukka Ollgren; Eeva Salo
Journal:  Euro Surveill       Date:  2021-03

3.  A systematic review of BCG vaccination policies among high-risk groups in low TB-burden countries: implications for vaccination strategy in Canadian indigenous communities.

Authors:  Lena Faust; Yoko Schreiber; Natalie Bocking
Journal:  BMC Public Health       Date:  2019-11-11       Impact factor: 3.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.